Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Travis Perkins: Total Voting Rights
Travis Perkins: Total Voting Rights
Travis Perkins: Total Voting Rights
DGAP-News: Adler Group S.A.: appeals against BaFin’s decision
DGAP-News: Adler Group S.A.: appeals against BaFin’s decision
DGAP-News: Adler Group S.A.: appeals against BaFin’s decision
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
DGAP-Adhoc: MAX Automation SE: ​​​​​​​Dusseldorf Regional Court grants application for court order to conduct a special audit and appoint a special auditor pursuant to Sec. 142 (2) AktG
DGAP-Adhoc: MAX Automation SE: ​​​​​​​Dusseldorf Regional Court grants application for court order to conduct a special audit and appoint a special auditor pursuant to Sec. 142 (2) AktG
DGAP-Adhoc: MAX Automation SE: ​​​​​​​Dusseldorf Regional Court grants application for court order to conduct a special audit and appoint a special auditor pursuant to Sec. 142 (2) AktG
PAO Severstal: Notice on Conference Call about Written Resolution issues for the Eurobond 2022
PAO Severstal: Notice on Conference Call about Written Resolution issues for the Eurobond 2022
PAO Severstal: Notice on Conference Call about Written Resolution issues for the Eurobond 2022
Rights and Issues Investment Trust PLC: Share Buyback Programme Extension
Rights and Issues Investment Trust PLC: Share Buyback Programme Extension
Rights and Issues Investment Trust PLC: Share Buyback Programme Extension
Hardman & Co Research: The Fulham Shore (Initiation of coverage): Platform ready for take-off
Hardman & Co Research: The Fulham Shore (Initiation of coverage): Platform ready for take-off
Hardman & Co Research: The Fulham Shore (Initiation of coverage): Platform ready for take-off
Rights and Issues Investment Trust PLC: Appointment of Corporate Broker
Rights and Issues Investment Trust PLC: Appointment of Corporate Broker
Rights and Issues Investment Trust PLC: Appointment of Corporate Broker
SThree: Total Voting Rights
SThree: Total Voting Rights
SThree: Total Voting Rights
Rights and Issues Investment Trust PLC: Half Year Report for the period to 30th June 2022
Rights and Issues Investment Trust PLC: Half Year Report for the period to 30th June 2022
Rights and Issues Investment Trust PLC: Half Year Report for the period to 30th June 2022
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Total Voting Rights
Rights and Issues Investment Trust PLC: Total Voting Rights
Rights and Issues Investment Trust PLC: Total Voting Rights
Invitation Half-Year 2022 Results Media and Investor Conference Call and Webcast
Invitation Half-Year 2022 Results Media and Investor Conference Call and Webcast
Invitation Half-Year 2022 Results Media and Investor Conference Call and Webcast
Halfords Group PLC: Director/PDMR Shareholding
Halfords Group PLC: Director/PDMR Shareholding
Halfords Group PLC: Director/PDMR Shareholding
Aroundtown SA: Release of a capital market information
Aroundtown SA: Release of a capital market information
Aroundtown SA: Release of a capital market information
DGAP-News: Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule
DGAP-News: Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule
DGAP-News: Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule
KYOCERA Announces Consolidated Financial Results for Three Months Ended June 30, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24000/Kyocera_logo.svg.png
KYOCERA Announces Consolidated Financial Results for Three Months Ended June 30, 2022


Kyocera Corporation (TOKYO:6971) today announced its consolidated financial results for the three months ended June 30, 2022 (the “first quarter,” or “FY23-Q1”), as summarized below. Complete

Ergomed (ERGO): Sustained growth momentum in H122
Ergomed (ERGO): Sustained growth momentum in H122
Ergomed (ERGO): Sustained growth momentum in H122
Bloc Ventures: Demand for deep tech unhindered by downturn
Bloc Ventures: Demand for deep tech unhindered by downturn
Bloc Ventures: Demand for deep tech unhindered by downturn
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q2 2022
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q2 2022
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q2 2022
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
DGAP-News: UniDevice AG: Month Sales Record
DGAP-News: UniDevice AG: Month Sales Record
DGAP-News: UniDevice AG: Month Sales Record
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements
DGAP-News: Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements
DGAP-News: Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements